Samar Samir Youssef
National Research Centre, Egypt
Title: miRNCDH- microRNA-516-3p, a novel circulating miRNA differentially expressed in HCV and HCV related HCC Egyptian patients
Biography
Biography: Samar Samir Youssef
Abstract
Liver disorders arising from Hepatitis C virus (HCV) infection are considered a key challenge in the fi eld of translational medicine. HCV and HCV related hepatocellular carcinoma (HCC) poses a heavy burden globally; pivoting on the geographical region, Egypt showed the highest prevalence of HCV worldwide. MicroRNAs (miRNAs) were found to regulate or be regulated by HCV infection. Recently, circulating miRNAs detected in human serum are proposed as novel class of biomarkers for diff erent pathological conditions. miR-516-3p is a novel miRNA that was not widely investigated in terms of infectious diseases rather than oncology. It was recently reported as antimetastamiR through activation of Wnt/B-catenin pathway in gastric cancer. However, among studies eff orts has been employed to investigate the alteration in the circulating miRNA pattern that is related with HCV infection and associated HCC, miR-516-3p is scarcely discussed. Moreover, this has not been investigated in case of Egyptian HCV patients or HCC patients. Th erefore, the aim of this study is to investigate the expression profi le of the novel liverassociated miRNA, miR-516-3p, in the serum of HCV and HCC Egyptian patients. Serum samples were collected from 50 HCV, 20 HCC Egyptian patients and 30 age-matched healthy controls. Total RNA was extracted using Geneaid total RNA mini-kit. Reverse transcription was performed using TaqMan® MicroRNA Reverse Transcription Kit. Finally, miR-516 expression was quantifi ed using qRT-PCR. Data was statistically analyzed using GraphPad Prism 5.00 soft ware. miR-516-3p was found to be signifi cantly up-regulated in HCV patients compared to agematched healthy controls (p=0.002). Also miR-516-3p showed statistically signifi cant upregulation in HCC versus HCV patients (p=0.0001). Th is study identifi es miR-516-3p as a novel circulating MicroRNA. miR-516-3p was found to be overexpressed in the serum of HCV patients. Moreover miR-516-3p showed escalated up regulation in HCC patients. Th us shedding the light on the pivotal role of miR-516-3p in HCV and HCV induced HCC.